These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2332982)

  • 21. In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species.
    Puigdemont A; Arboix M; Gaspari F; Bortolotti A; Bonati M
    Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):435-40. PubMed ID: 2781140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Low-dose propafenone in chronic ventricular arrhythmia: evaluation by linear regression analysis and correlation with the plasma concentrations of the drug].
    Vitale P; De Stefano R; Perna B; Romano A; Iacono A
    Cardiologia; 1986 Apr; 31(4):303-10. PubMed ID: 3791323
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enantioselective determination of diprafenone in human plasma.
    Zhong D; Chen R; Fieger-Büschges H; Blume H
    Pharmazie; 1997 Feb; 52(2):106-9. PubMed ID: 9122271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans.
    Sasaki S; Koumi S; Sato R; Murata M; Nagasawa K; Sakurai E; Hikichi N; Hayakawa H
    Gen Pharmacol; 1998 Oct; 31(4):589-91. PubMed ID: 9792220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites.
    Volz M; Mitrovic V; Thiemer J; Schlepper M
    Arzneimittelforschung; 1995 Mar; 45(3):246-9. PubMed ID: 7741777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE; Philippon F; Gilbert M; Champagne J; Michaud V; Charbonneau L; Pruneau G; Hamelin BA; Geelen P; Turgeon J
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    Cai WM; Chen B; Cai MH; Chen Y; Zhang YD
    Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis.
    Hamidi M
    Drug Dev Ind Pharm; 2010 Mar; 36(3):355-61. PubMed ID: 19722914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propafenone disposition during continuous venovenous hemofiltration.
    Seto W; Trope AE; Gow RM
    Ann Pharmacother; 1999 Sep; 33(9):957-9. PubMed ID: 10492500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of yohimbine following intravenous administration to horses.
    Dimaio Knych HK; Steffey EP; Deuel JL; Shepard RA; Stanley SD
    J Vet Pharmacol Ther; 2011 Feb; 34(1):58-63. PubMed ID: 21219345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
    Giani P; Landolina M; Giudici V; Bianchini C; Ferrario G; Marchi S; Riva E; Latini R
    Eur J Clin Pharmacol; 1988; 34(2):187-94. PubMed ID: 3383990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography.
    Shirayama Y; Doki K; Sekiguchi Y; Aonuma K; Kohda Y; Homma M
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28929504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of intravenous medetomidine in the horse.
    Grimsrud KN; Mama KR; Steffey EP; Stanley SD
    Vet Anaesth Analg; 2012 Jan; 39(1):38-48. PubMed ID: 22103480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.
    Mesnil F; Dubruc C; Mentre F; Huet S; Mallet A; Thenot JP
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):125-47. PubMed ID: 9408856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.